Osimertinib Approved for First-Line Treatment in Metastatic NSCLC

被引：0
|
作者：
Schuyler, Devon
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2018年 / 16卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：397 / 397
页数：1
相关论文
共 50 条
  • [1] Pembrolizumab (Keytruda) for First-Line Treatment of Metastatic NSCLC
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2017, 59 (1513): : 4 - 5
  • [2] Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
    Socinski, M. A.
    Jotte, R. M.
    Cappuzzo, F.
    Orlandi, F.
    Stroyakovskiy, D.
    Nogami, N.
    Rodriguez-Abreu, D.
    Moro-Sibilot, D.
    Thomas, C. A.
    Barlesi, F.
    Finley, G.
    Kelsch, C.
    Lee, A.
    Coleman, S.
    Deng, Y.
    Shen, Y.
    Kowanetz, M.
    Lopez-Chavez, A.
    Sandler, A.
    Reck, M.
    Ahualli, A.
    Jarchum, G.
    Kaen, D. L.
    Kahl, S.
    Kotliar, M.
    Kowalyszyn, R. D.
    Lerzo, G.
    Magri, I
    Martin, C.
    Pastor, A.
    Picon, P.
    Streich, G.
    Varela, M.
    Blinman, P.
    Boyer, M.
    Crombie, C.
    Gauden, S.
    Gill, S.
    Hughes, B.
    John, T.
    Joshi, A.
    Kosmider, S.
    Lewis, C.
    Millward, M.
    Nordman, I
    Nott, L.
    O'Byrne, K.
    Parnis, F.
    Potasz, N.
    Richardson, G.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (24): : 2288 - 2301
  • [3] Ipilimumab-nivolumab as first-line treatment in metastatic NSCLC
    El-Ghazzi, Nathan
    Lavaud, Pernelle
    [J]. BULLETIN DU CANCER, 2021, 108 (03) : 231 - 233
  • [4] Nivolumab plus ipilimumab for the first-line treatment of metastatic NSCLC
    Rijavec, Erika
    Indini, Alice
    Ghidini, Michele
    Tomasello, Gianluca
    Cattaneo, Monica
    Barbin, Francesca
    Grossi, Francesco
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (07) : 705 - 713
  • [5] Treatment options after first-line immunotherapy in metastatic NSCLC
    Santos, Edgardo S.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2020, 20 (03) : 221 - 228
  • [6] CNS Control after First-Line Osimertinib in Patients with Metastatic EGFR-Mutant NSCLC
    Hui, C.
    Wakelee, H. A.
    Neal, J. W.
    Ramchandran, K. J.
    Das, M.
    Nagpal, S.
    Roy, M.
    Huang, J.
    Pollom, E.
    Myall, N.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E110 - E110
  • [7] Distinct Progression and Efficacy of First-Line Osimertinib Treatment According to Mutation Subtypes in Metastatic NSCLC Harboring EGFR Mutations
    Takeyasu, Yuki
    Yoshida, Tatsuya
    Masuda, Ken
    Matsumoto, Yuji
    Shinno, Yuki
    Okuma, Yusuke
    Goto, Yasushi
    Horinouchi, Hidehito
    Yamamoto, Noboru
    Ohe, Yuichiro
    [J]. JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (02):
  • [8] New Approved First-line Combining Therapy of NSCLC in 2020
    Wang, Nianwu
    Wang, Wei
    Mao, Wenli
    Wang, Kefeng
    Zhang, Haozhe
    Ma, Qiang
    Kuerbantayi, Nazuke
    Wang, Yukun
    [J]. 2021 5TH INTERNATIONAL CONFERENCE ON ADVANCES IN ENERGY, ENVIRONMENT AND CHEMICAL SCIENCE (AEECS 2021), 2021, 245
  • [9] Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
    Scott L.J.
    [J]. Drugs & Therapy Perspectives, 2018, 34 (8) : 351 - 357
  • [10] Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR plus NSCLC
    Lim, Sun Min
    Lee, Jii Bum
    Cho, Byoung Chul
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (03) : 376 - 379
12345